Axon Enterprise — May 6, 2026 release
Fiscal 2026 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001628280-26-031285
Showing in the filing
Portion of future contracted bookings expected to be fulfilled
“between 20% and 25%”
Period
No period stated
Measure
Company-defined measure
Source
Prose
All guidance in this release · 10
Adjusted EBITDA margin for FY2026
“25.5%”
Operating cash flow for FY2026
“over $600 million”
Operating cash flow for FY2026
“over $600 million”
Free cash flow for FY2026
“approximately $450 million”
Free cash flow for FY2026
“approximately $450 million”
Portion of future contracted bookings expect…
“between 20% and 25%”
Revenue growth for FY2026
“a range of 30% to 32%”
Stock-based compensation expense for FY2026
“approximately $590 million to $620 million”
Stock-based compensation expense related to … for FY2026
“approximately $230 million”
CapEx for FY2026
“$160 million to $190 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
This operational metric tracks total unfulfilled contracted bookings for products and services, including remaining performance obligations as well as contracts with certain ter mination or other clauses that are not otherwise included in remaining performance obligations. We expect to fulfill between 20% and 25% of this balance over the next 12 months and generally expect the remainder to be fulfilled over the following ten years. 2026 Outlook The following forward-looking statements reflect Axon’s expectations as of May 6, 2026 and are subject to risks and uncertainties. Please refer to “ Forward-Looking Statements ” below for additional information. • 2026 Revenue: Axon expects full-year 2026 revenue growth in a range of 30% to 32%, an increase from 27% to 30% previously. • 2026 Adjusted EBITDA: Axon expects full-year 2026 Adjusted EBITDA margin of 25.5%, in line with prior margin guidance. ◦ We provide Adjusted EBITDA guidance, rather than net income guidance, due to the inherent difficulty of forecasting certain types of expenses and gains such as income tax expenses and gains or losses on marketable securities and strategic investments, which affect net income but not Adjusted EBITDA. We are unable to reasonably estimate the impact of such expenses, which could be material, on net income. Accordingly, we do not provide a reconciliation of projected net income to projected Adjusted EBITDA. • 2026 Stock-based compensation: Axon expects full-year 2026 stock-based compensation expenses t
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.